For COVID-19 vaccine updates, please review our information guide. For patient eligibility and scheduling availability, please visit VaccineTogetherNY.org.

You are here

Publications

Found 47 results
Author Title [ Type(Asc)] Year
Filters: Author is Moore, John P  [Clear All Filters]
Journal Article
Berro R, Klasse PJohan, Lascano D, Flegler A, Nagashima KA, Sanders RW, Sakmar TP, Hope TJ, Moore JP.  2011.  Multiple CCR5 conformations on the cell surface are used differentially by human immunodeficiency viruses resistant or sensitive to CCR5 inhibitors.. J Virol. 85(16):8227-40.
Behrens A-J, Harvey DJ, Milne E, Cupo A, Kumar A, Zitzmann N, Struwe WB, Moore JP, Crispin M.  2017.  Molecular Architecture of the Cleavage-Dependent Mannose Patch on a Soluble HIV-1 Envelope Glycoprotein Trimer.. J Virol. 91(2)
Burton DR, Hessell AJ, Keele BF, Klasse PJohan, Ketas TA, Moldt B, D Dunlop C, Poignard P, Doyle LA, Cavacini L et al..  2011.  Limited or no protection by weakly or nonneutralizing antibodies against vaginal SHIV challenge of macaques compared with a strongly neutralizing antibody.. Proc Natl Acad Sci U S A. 108(27):11181-6.
Eggink D, Melchers M, Wuhrer M, van Montfort T, Dey AK, Naaijkens BA, David KB, Le Douce V, Deelder AM, Kang K et al..  2010.  Lack of complex N-glycans on HIV-1 envelope glycoproteins preserves protein conformation and entry function.. Virology. 401(2):236-47.
Ringe RP, Yasmeen A, Ozorowski G, Go EP, Pritchard LK, Guttman M, Ketas TA, Cottrell CA, Wilson IA, Sanders RW et al..  2015.  Influences on the Design and Purification of Soluble, Recombinant Native-Like HIV-1 Envelope Glycoprotein Trimers.. J Virol. 89(23):12189-210.
Pugach P, Ray N, Klasse PJohan, Ketas TJ, Michael E, Doms RW, Lee B, Moore JP.  2009.  Inefficient entry of vicriviroc-resistant HIV-1 via the inhibitor-CCR5 complex at low cell surface CCR5 densities.. Virology. 387(2):296-302.
Banerjee K, Klasse PJ, Sanders RW, Pereyra F, Michael E, Lu M, Walker BD, Moore JP.  2010.  IgG subclass profiles in infected HIV type 1 controllers and chronic progressors and in uninfected recipients of Env vaccines.. AIDS Res Hum Retroviruses. 26(4):445-58.
Klasse PJohan, Sanders RW, Cerutti A, Moore JP.  2012.  How can HIV-type-1-Env immunogenicity be improved to facilitate antibody-based vaccine development? AIDS Res Hum Retroviruses. 28(1):1-15.
Sanders RW, van Gils MJ, Derking R, Sok D, Ketas TJ, Burger JA, Ozorowski G, Cupo A, Simonich C, Goo L et al..  2015.  HIV-1 VACCINES. HIV-1 neutralizing antibodies induced by native-like envelope trimers.. Science. 349(6244):aac4223.
Klasse PJ, Ketas TJ, Cottrell CA, Ozorowski G, Debnath G, Camara D, Francomano E, Pugach P, Ringe RP, LaBranche CC et al..  2018.  Epitopes for neutralizing antibodies induced by HIV-1 envelope glycoprotein BG505 SOSIP trimers in rabbits and macaques.. PLoS Pathog. 14(2):e1006913.
Banerjee K, Andjelic S, Klasse PJohan, Kang Y, Sanders RW, Michael E, Durso RJ, Ketas TJ, Olson WC, Moore JP.  2009.  Enzymatic removal of mannose moieties can increase the immune response to HIV-1 gp120 in vivo.. Virology. 389(1-2):108-21.
Ketas TJ, Holuigue S, Matthews K, Moore JP, Klasse PJohan.  2012.  Env-glycoprotein heterogeneity as a source of apparent synergy and enhanced cooperativity in inhibition of HIV-1 infection by neutralizing antibodies and entry inhibitors.. Virology. 422(1):22-36.
Ketas TJ, Schader SM, Zurita J, Teo E, Polonis V, Lu M, Klasse PJohan, Moore JP.  2007.  Entry inhibitor-based microbicides are active in vitro against HIV-1 isolates from multiple genetic subtypes.. Virology. 364(2):431-40.
Ozorowski G, Cupo A, Golabek M, LoPiccolo M, Ketas TA, Cavallary M, Cottrell CA, Klasse PJ, Ward AB, Moore JP.  2018.  Effects of Adjuvants on HIV-1 Envelope Glycoprotein SOSIP Trimers .. J Virol. 92(13)
Moore JP, Klasse PJ.  2020.  COVID-19 Vaccines: "Warp Speed" Needs Mind Melds, Not Warped Minds.. J Virol. 94(17)
Ringe RP, Pugach P, Cottrell CA, LaBranche CC, Seabright GE, Ketas TJ, Ozorowski G, Kumar S, Schorcht A, van Gils MJ et al..  2019.  Closing and Opening Holes in the Glycan Shield of HIV-1 Envelope Glycoprotein SOSIP Trimers Can Redirect the Neutralizing Antibody Response to the Newly Unmasked Epitopes.. J Virol. 93(4)
van Montfort T, Melchers M, Isik G, Menis S, Huang P-S, Matthews K, Michael E, Berkhout B, Schief WR, Moore JP et al..  2011.  A chimeric HIV-1 envelope glycoprotein trimer with an embedded granulocyte-macrophage colony-stimulating factor (GM-CSF) domain induces enhanced antibody and T cell responses.. J Biol Chem. 286(25):22250-61.
Dey AK, Cupo A, Ozorowski G, Sharma VK, Behrens A-J, Go EP, Ketas TJ, Yasmeen A, Klasse PJ, Sayeed E et al..  2018.  cGMP production and analysis of BG505 SOSIP.664, an extensively glycosylated, trimeric HIV-1 envelope glycoprotein vaccine candidate.. Biotechnol Bioeng. 115(4):885-899.
Dey AK, David KB, Lu M, Moore JP.  2009.  Biochemical and biophysical comparison of cleaved and uncleaved soluble, trimeric HIV-1 envelope glycoproteins.. Virology. 385(1):275-81.
Klasse PJohan, Shattock R, Moore JP.  2008.  Antiretroviral drug-based microbicides to prevent HIV-1 sexual transmission.. Annu Rev Med. 59:455-71.
Kaner RJ, Santiago F, Rahaghi F, Michaels E, Moore JP, Crystal RG.  2010.  Adenovirus vectors block human immunodeficiency virus-1 replication in human alveolar macrophages by inhibition of the long terminal repeat.. Am J Respir Cell Mol Biol. 43(2):234-42.
Ingallinella P, Bianchi E, Ladwa NA, Wang Y-J, Hrin R, Veneziano M, Bonelli F, Ketas TJ, Moore JP, Miller MD et al..  2009.  Addition of a cholesterol group to an HIV-1 peptide fusion inhibitor dramatically increases its antiviral potency.. Proc Natl Acad Sci U S A. 106(14):5801-6.